EUVIMEDEUVIMED entdecken
Crossref

Revolutionary changes in GINA 2019 report – one inhaler in maintenance and reliever therapy for the majority of asthmatic patients

Andrzej Emeryk, Justyna Emeryk-Maksymiuk

Alergoprofil · 2019

DOI: 10.24292/01.ap.152200619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alergoprofil, 2019. Verfasst von Andrzej Emeryk und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The GINA 2019 report introduces revolutionary changes in the pharmacotherapy of asthma in children > 5 years old, adolescents and adults. For safety reasons, experts from the GINA 2019 report no longer recommend the use of short-acting b2-agonists (SABA) as monotherapy, but in combination with inhaled corticosteroid (ICS). In all adults and children ≥ 12 years of age, the preferred control treatment is ICS in a dose dependent on asthma symptoms or ICS with formoterol in the SMART/MART regimen (maintenance and rescue therapy from the same inhaler). The alternative is ICS with long-acting b2-agonist in “rigid” dosing and SABA “as needed”. The optimal treatment method for the vast majority of asthmatics aged ≥ 12 years is currently SMART/MART therapy, which most effectively prevents asthma exacerbations. It can be carried out using budesonide with formoterol from dry powder inhalers (Easyhaler®, Turbuhaler® and Spiromax®) or beclometasone with formoterol from a pressurised metered dose inhaler.

Zitieren

APA

Emeryk, A., & Emeryk-Maksymiuk, J. (2019). Revolutionary changes in GINA 2019 report – one inhaler in maintenance and reliever therapy for the majority of asthmatic patients. Alergoprofil. https://doi.org/10.24292/01.ap.152200619

Vancouver

Emeryk A, Emeryk-Maksymiuk J. Revolutionary changes in GINA 2019 report – one inhaler in maintenance and reliever therapy for the majority of asthmatic patients. Alergoprofil. 2019. doi:10.24292/01.ap.152200619

BibTeX
@article{Emeryk2019,
  author = {Emeryk, Andrzej and Emeryk-Maksymiuk, Justyna},
  title = {Revolutionary changes in GINA 2019 report – one inhaler in maintenance and reliever therapy for the majority of asthmatic patients},
  journal = {Alergoprofil},
  year = {2019},
  doi = {10.24292/01.ap.152200619}
}
Kostenlos starten →